Skip to main content

Table 1 Baseline patient, disease, and transplant characteristics

From: Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia

  MMUD (N = 280) CBT (N = 902) p value
Follow-up (reverse KM, months)
Median (IQR) 19.1 (11.4–36.7) 46.8 (22.6–72.6) < 0.001
Patient age (years)    
Median (min–max) [IQR] 52.1 (18.2–75.6) [39.9–61.2] 50.5 (18.1–73.2) [38.4–60.3] 0.087
Year transplant
Median (min–max) [IQR] 2017 (2010–2019) 2013 (2010–2019) < 0.001
Cytogenetics risk groupa    
Good risk 18 (6.4%) 50 (5.5%) 0.001
Intermediate risk 148 (52.9%) 366 (40.6%)  
Adverse risk 40 (14.3%) 144 (16%)  
Unknown risk 74 (26.4%) 342 (37.9%)  
Disease status at transplantation
CR1 179 (63.9%) 522 (57.9%) 0.023
CR2 + 49 (17.5%) 230 (25.5%)  
Advanced 52 (18.6%) 150 (16.6%)  
Patient gender    
Male 163 (58.2%) 430 (47.7%) 0.002
Donor gender    
Male 187 (68.2%) 421 (50%) < 0.001
Missing 6 60  
Female donor to male recipient
  35 (12.7%) 194 (22.2%) < 0.001
Missing 5 29  
HCT-CI
0 125 (59%) 294 (57.3%) 0.073
1 or 2 32 (15.1%) 112 (21.8%)  
≥ 3 55 (25.9%) 107 (20.9%)  
Missing 68 389  
KPS score
≥ 90 76 (27.1%) 210 (23.3%) 0.19
Patient CMV serostatus: positive
Positive 201 (73.6%) 587 (66.9%) 0.036
Missing 7 24  
Donor CMV serostatus: positive
Positive 127 (45.8%) 260 (35.2%) 0.002
Missing 3 163  
Graft source
  BM—19 (6.8%) Single unit—408 (45.2%)  
  PBSC—261 (93.2%) Double unit—494 (54.8%)  
Conditioning regimen intensity
MAC 141 (50.4%) 416 (46.1%) 0.21
RIC 139 (49.6%) 486 (53.9%)  
Type of conditioning regimen
BuCy 14 (5%) 23 (2.5%) < 0.001
BuFlu 116 (41.4%) 14 (1.6%)  
TBF 45 (16.1%) 263 (29.2%)  
TBI-based 38 (13.6%) 522 (57.9%)  
Other 67 (23.9%) 80 (8.9%)  
GVHD prophylaxisb
csa + mmf 111 (39.6%) 638 (70.7%)  
tacro + mmf 51 (18.2%) 22 (2.4%)  
csa + mtx 10 (3.6%) 35 (3.9%)  
csa 34 (12.1%) 183 (20.3%)  
tacro 24 (8.6%) 2 (0.2%)  
siro + mmf 14 (5%) 8 (0.9%)  
other 36 (12.9%) 14 (1.6%)  
  1. CMV cytomegalovirus; GVHD graft-versus-host disease, KPS Karnofsky performance status, HCT-CI hematopoietic cell transplantation comorbidity index, KM Kaplan–Meier, IQR interquartile rage, BM bone marrow, PBSC peripheral blood stem cell, MAC myeloablative conditioning, RIC reduced-intensity conditioning, BuCy busulfan cyclophosphamide, BuFu busulfan, fludarabine, TBF thiotepa, busulfan, fludarabine, TBI total body irradiation, CSA cyclosporine, mtx methotrexate, mmf mycophenolate mofetil, tacro tacrolimus, siro sirolimus
  2. aPer UK MRC criteria
  3. bAll MMUD patients received PTCy